BURNING ROCK BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 USD | -0.01% |
|
+18.06% | -8.60% |
| Apr. 02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M | MT |
| Apr. 02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Capitalization 1 | 15,646 | 6,329 | 1,632 |
| Enterprise Value (EV) 1 | 13,430 | 4,919 | 775.6 |
| P/E ratio | -21.9 x | -7.92 x | -1.66 x |
| Yield | - | - | - |
| Capitalization / Revenue | 36.4 x | 12.5 x | 2.9 x |
| EV / Revenue | 31.2 x | 9.68 x | 1.38 x |
| EV / EBITDA | -35.3 x | -6.54 x | -0.9 x |
| EV / FCF | -620,885,807 x | -16,113,195 x | -3,522,870 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 6.52 x | 3.45 x | 1.38 x |
| Nbr of stocks (in thousands) | 103,805 | 104,548 | 105,188 |
| Reference price 2 | 150.7 | 60.54 | 15.52 |
| Announcement Date | 3/23/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 111.2 | 208.9 | 381.7 | 429.9 | 507.9 | 563.2 |
| EBITDA 1 | -99.84 | -136.9 | -138.3 | -379.9 | -752.5 | -859.7 |
| EBIT 1 | -120.9 | -161.4 | -169.1 | -412.4 | -797.1 | -980.4 |
| Operating Margin | -108.73% | -77.27% | -44.3% | -95.93% | -156.94% | -174.07% |
| Earnings before Tax (EBT) 1 | -131.3 | -177.5 | -169.2 | -407.2 | -795.8 | -969.2 |
| Net income 1 | -131.3 | -177.5 | -169.2 | -407.2 | -796.7 | -971.2 |
| Net margin | -118.09% | -84.98% | -44.32% | -94.73% | -156.87% | -172.44% |
| EPS 2 | -10.20 | -10.38 | -14.23 | -6.876 | -7.645 | -9.347 |
| Free Cash Flow | - | -111.4 | -222.1 | -21.63 | -305.3 | -220.2 |
| FCF margin | - | -53.34% | -58.2% | -5.03% | -60.11% | -39.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/9/19 | 12/9/19 | 5/22/20 | 3/23/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Net sales 1 | 127.3 | 126.6 | 147.3 | 135.5 | 130.8 | 154.6 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -202 | -171 | - | -262.9 | - | -234.6 |
| Operating Margin | -158.73% | -135.09% | - | -193.96% | - | -151.74% |
| Earnings before Tax (EBT) 1 | - | - | - | -261.4 | - | -231.5 |
| Net income 1 | - | - | - | -261.4 | - | -231.5 |
| Net margin | - | - | - | -192.87% | - | -149.7% |
| EPS 2 | - | - | - | -2.500 | -2.500 | -2.330 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/31/21 | 11/16/21 | 3/22/22 | 5/31/22 | 8/31/22 | 11/16/22 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 136 | - | - | - | - |
| Net Cash position 1 | 21.3 | - | 343 | 2,216 | 1,410 | 857 |
| Leverage (Debt/EBITDA) | - | -0.9936 x | - | - | - | - |
| Free Cash Flow | - | -111 | -222 | -21.6 | -305 | -220 |
| ROE (net income / shareholders' equity) | - | -220% | -51.9% | -26.4% | -37.3% | -64.7% |
| ROA (Net income/ Total Assets) | - | -26.1% | -17.3% | -14.7% | -20.2% | -31.7% |
| Assets 1 | - | 680.1 | 976.6 | 2,773 | 3,951 | 3,064 |
| Book Value Per Share 2 | -20.60 | -26.00 | -35.60 | 23.10 | 17.60 | 11.30 |
| Cash Flow per Share 2 | 3.030 | 4.030 | 3.760 | 18.10 | 13.60 | 8.820 |
| Capex 1 | 22.4 | 24.6 | 45.3 | 75.6 | 211 | 70.3 |
| Capex / Sales | 20.19% | 11.76% | 11.88% | 17.58% | 41.53% | 12.48% |
| Announcement Date | 12/9/19 | 12/9/19 | 5/22/20 | 3/23/21 | 4/29/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -8.60% | 89.62M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- BNR Stock
- Financials Burning Rock Biotech Limited
